

1 CLAIMS

2 What is claimed is:

3
4 Claim 1. A biopolymer marker selected from the group
5 consisting of sequence ID ^{SEQ ID NO: 1} ~~(K)SPEQOETVLDGNLIIR(Y)~~, or
6 ^{SEQ ID NO: 2} ~~(K)QHPCLDGSAGR(N)~~ or at least one analyte thereof [useful
7 in indicating at least one particular disease state.]
8

9 Claim 2. The biopolymer marker of claim 1 wherein
10 said disease state is predictive of Alzheimers disease.
11

12 Claim 3. A method for evidencing and categorizing at
13 least one disease state comprising:

14 obtaining a sample from a patient;

15 conducting mass spectrometric analysis on said
16 sample;

17 evidencing and categorizing at least one biopolymer
18 marker sequence or analyte thereof isolated from said
19 sample; and,

20 comparing said at least one isolated biopolymer
21 marker sequence or analyte thereof to the biopolymer
22 marker sequence as set forth in claim 1;

23 wherein correlation of said isolated biopolymer
24 marker and said biopolymer marker sequence as set forth in

1 claim 1 evidences and categorizes said at least one
2 disease state.

3

4 Claim 4. The method of claim 3, wherein said step
5 of evidencing and categorizing is particularly directed to
6 biopolymer markers or analytes thereof linked to at least
7 one risk of disease development of said patient.

8

9 Claim 5. The method of claim 3, wherein said step
10 of evidencing and categorizing is particularly directed to
11 biopolymer markers or analytes thereof related to the
12 existence of a particular disease state.

13

14 Claim 6. The method of claim 3, wherein the sample
15 is an unfractionated body fluid or a tissue sample.

16

17

18 Claim 7. The method of claim 3, wherein said sample
19 is at least one of the group consisting of blood, blood
20 products, urine, saliva, cerebrospinal fluid, and lymph.

21

22 Claim 8. The method of claim 3, wherein said mass
23 spectrometric analysis is selected from the group
24 consisting of Surface Enhanced Laser Desorption Ionization

1 (SELDI) mass spectrometry (MS), Maldi Qq TOF, MS/MS,
2 TOF-TOF, and ESI-Q-TOF or an ION-TRAP.

3
4 Claim 9. The method of claim 3, wherein said
5 patient is a human.

6
7 Claim 10. A diagnostic assay kit [for determining
8 the presence of the biopolymer marker or analyte thereof
9 of claim 1] comprising:

10 at least one biochemical material which is capable of
11 specifically binding with a biomolecule which includes at
12 least said biopolymer marker or analyte thereof, and
13 means for determining binding between said
14 biochemical material and said biomolecule;

15 whereby at least one analysis to determine a presence
16 of a marker, analyte thereof, or a biochemical material
17 specific thereto, is carried out on a sample.

18 *intended use*

19 Claim 11. The diagnostic assay kit of claim 10,
20 wherein said biochemical material or biomolecule is
21 immobilized on a solid support.

22
23 Claim 12. The diagnostic assay kit of claim 10
24 including:

09992067-113101

1 at least one labeled biochemical material.

2
3 Claim 13. The diagnostic assay kit of claim 10,
4 wherein said biochemical material is an antibody.

5
6 Claim 14. The diagnostic assay kit of claim 12,
7 wherein said labeled biochemical material is an antibody.

8
9 Claim 15. The diagnostic assay kit of claim 10,
10 wherein the sample is an unfractionated body fluid or a
11 tissue sample. *not positive limitation of*

12 *kit of claim 10*

13 Claim 16. The diagnostic assay kit of claim 10,
14 wherein said sample is at least one of the group
15 consisting of blood, blood products, urine, saliva,
16 cerebrospinal fluid, and lymph.

17
18 Claim 17. The diagnostic assay kit of claim 10,
19 wherein said biochemical material is at least one
20 monoclonal antibody specific therefore.

21
22 Claim 18. A kit [for diagnosing, determining risk-
23 assessment, and identifying therapeutic avenues related to
24 a disease state] comprising:

0992067-1101
FOOTER

1 at least one biochemical material which is capable of
2 specifically binding with a biomolecule which includes at
3 least one biopolymer marker selected from the group
4 consisting of sequence ID ^{SEQ ID No. 1} ~~(K) SPEQOETVLDGNLIIR(Y)~~,
5 ^{SEQ ID No. 2} ~~(K) QHPCLDGSAGR(N)~~ or at least one analyte thereof related
6 to said disease state; and

7 means for determining binding between said ^{label}
8 biochemical material and said biomolecule;
9 whereby at least one analysis to determine a presence
10 of a marker, analyte thereof, or a biochemical material
11 specific thereto, is carried out on a sample.

12
13 Claim 19. The kit of claim 18, wherein said
14 biochemical material or biomolecule is immobilized on a
15 solid support.

16
17 Claim 20. The kit of claim 18 including:
18 at least one labeled biochemical material.

19
20 Claim 21. The kit of claim 18, wherein said
21 biochemical material is an antibody.

22
23 Claim 22. The kit of claim 20, wherein said labeled
24 biochemical material is an antibody.

1 Claim 23. The kit of claim 18, wherein the sample is
2 an unfractionated body fluid or a tissue sample.

3 *not (+) limitation*

4 Claim 24. The kit of claim 18, wherein said sample
5 is at least one of the group consisting of blood, blood
6 products, urine, saliva, cerebrospinal fluid, and lymph.

7
8 Claim 25. The kit of claim 18, wherein said
9 biochemical material is at least one monoclonal antibody
10 specific therefore.

11
12 Claim 26. The kit of claim 18, wherein said
13 diagnosing, determining risk assessment, and identifying
14 therapeutic avenues is carried out on a single sample.

15 *intended use*

16 Claim 27. The kit of claim 18, wherein said
17 diagnosing, determining risk assessment, and identifying
18 therapeutic avenues is carried out on multiple samples
19 such that at least one analysis is carried out on a first
20 sample and at least another analysis is carried out on a
21 second sample.

22 *not (+) limitation*

23 Claim 28. The kit of claim 27, wherein said first
24 and second samples are obtained at different time periods.

1 Claim 29. Polyclonal antibodies produced against a
2 marker sequence ID selected from the group consisting of
3 sequence ID, ^{SEQ ID NO: 1} ~~(K)SPEQQETVLDGNLIIR(Y)~~, ^{SEQ ID NO: 2} ~~(K)QHPCLDGSAGR(N)~~ or
4 at least one analyte thereof in at least one animal host.

5
6 Claim 30. An antibody that specifically binds a
7 biopolymer including a marker selected from the group
8 consisting of sequence ID ^{SEQ ID NO: 1} ~~(K)SPEQQETVLDGNLIIR(Y)~~,
9 ^{SEQ ID NO: 2} ~~(K)QHPCLDGSAGR(N)~~ or at least one analyte thereof.

10
11 Claim 31. The antibody of claim 30 that is a
12 monoclonal antibody.

13
14 Claim 32. The antibody of claim 30 that is a
15 polyclonal antibody.

16
17 Claim 33. A process for identifying therapeutic
18 avenues related to a disease state comprising:

19 conducting an analysis as provided by the kit of
20 claim 18; and

21 interacting with a biopolymer selected from the group
22 consisting of sequence ID, ^{SEQ ID NO: 1} ~~(K)SPEQQETVLDGNLIIR(Y)~~,
23 ^{SEQ ID NO: 2} ~~(K)QHPCLDGSAGR(N)~~ or at least one analyte thereof;
24 whereby therapeutic avenues are developed.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Claim 34. The process for identifying therapeutic

avenues related to a disease state in accordance with

claim 33, wherein said therapeutic avenues regulate the

presence or absence of the biopolymer selected from the

group consisting of sequence ID ^{SEQ ID No. 1} ~~(K)SPEQQETVLDCNLIIR(V)~~,

^{SEQ ID No. 2} ~~(K)QHPCLDGSAGR(N)~~ or at least one analyte thereof.

Claim 35. The process for identifying therapeutic

avenues related to a disease state in accordance with

claim 33, wherein said therapeutic avenues developed

include at least one avenue selected from a group

consisting of 1)utilization and recognition of said

biopolymer markers, variants or moieties thereof as direct

therapeutic modalities, either alone or in conjunction

with an effective amount of a pharmaceutically effective

carrier; 2)validation of therapeutic modalities or disease

preventative agents as a function of biopolymer marker

presence or concentration; 3)treatment or prevention of a

disease state by formation of disease intervention

modalities; 4)use of biopolymer markers or moieties

thereof as a means of elucidating therapeutically viable

agents, 5)instigation of a therapeutic immunological

response; and 6) synthesis of molecular structures related

1 to said biopolymer markers, moieties or variants thereof
2 which are constructed and arranged to therapeutically
3 intervene in said disease state.
4

5 Claim 36. The process for identifying therapeutic
6 avenues related to a disease state in accordance with
7 claim 35, wherein said treatment or prevention of a
8 disease state by formation of disease intervention
9 modalities is the formation of biopolymer/ligand
10 conjugates which intervene at receptor sites to prevent,
11 delay or reverse a disease process.
12

13 Claim 37. The process for identifying therapeutic
14 avenues related to a disease state in accordance with
15 claim 35, wherein said means of elucidating
16 therapeutically viable agents includes use of a
17 bacteriophage peptide display library or a bacteriophage
18 antibody library.
19

20 Claim 38. A process for regulating a disease state
21 by controlling the presence or absence of a biopolymer
22 selected from the group consisting of sequence ID
23 ~~SEQ ID No: 1 (K) SPEQOETVLDGNLIIR(Y)~~ ~~SEQ ID No: 2 (K) OHPCLDGSAGR(N)~~ or at least one
24 analyte thereof.